EASTWAY PHARMA LTD

PRI/LTD BY GUAR/NSC (Private, limited by guarantee, no share capital)

This company is commonly known as Eastway Pharma Ltd. The company was founded 5 years ago and was given the registration number 12080557. The firm's registered office is in MANCHESTER. You can find them at Suite 61 Cariocca Business Park, 2 Hellidon Close, Manchester, . This company's SIC code is 47730 - Dispensing chemist in specialised stores.

Company Information

Name	:	EASTWAY PHARMA LTD
Company Number	:	12080557
Company Type	:	PRI/LTD BY GUAR/NSC (Private, limited by guarantee, no share capital)
Status	:	Active
Incorporation Date	:	02 July 2019
End of financial year	:	31 July 2023
Jurisdiction	:	England - Wales
Industry Codes	:	47730 - Dispensing chemist in specialised stores

Office Address & Contact

Registered Address	:	Suite 61 Cariocca Business Park, 2 Hellidon Close, Manchester, United Kingdom, M12 4AH
Country Origin	:	UNITED KINGDOM
Telephone	:	Unreported
Email Address	:	Unreported
Website	:	Unreported
Social	:	Unreported

People with Significant Control

Mr Shahzad Akram
Notified on	:	02 July 2019
Status	:	Active
Date of birth	:	November 1976
Nationality	:	British
Country of residence	:	United Kingdom
Address	:	2, Eastway, Sale, United Kingdom, M33 4DX
Nature of control	:	Ownership of shares 25 to 50 percent Voting rights 25 to 50 percent Right to appoint and remove directors

Mr Mustafa Suleiman Hussein
Notified on	:	02 July 2019
Status	:	Active
Date of birth	:	October 1972
Nationality	:	British
Country of residence	:	United Kingdom
Address	:	2, Eastway, Sale, United Kingdom, M33 4DX
Nature of control	:	Ownership of shares 25 to 50 percent Voting rights 25 to 50 percent Right to appoint and remove directors

Account Documents

Accounts

Last accounts submitted for period 31 March 2023 (1 year ago)
Accounts type was MICRO
Next accounts dated 31 March 2024
Due by 31 December 2024 (1 months remaining)

Confirmation Statement

Last submitted on 14 October 2023 (1 year ago)
Next confirmation dated 14 October 2024
Due by 28 October 2024 (0 months remaining)